Overview

Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

Status:
Completed

Trial end date:
2017-11-29

Target enrollment:

Participant gender:

Summary

This is a Phase 1, single center, fixed sequence, open label, drug-drug interaction study of the effect of multiple doses of rifampin 600 mg daily, a strong CYP3A inducer, on the exposure of mifepristone at 2 dose levels.

Phase:

Phase 1

Details

Lead Sponsor:

Corcept Therapeutics

Treatments:

Mifepristone
Rifampin